Pressure BioSciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events	3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	7) Subsequent Events From April 1, 2023 through May 10, 2023 the Company entered into five (5) new merchant cash loan agreements collecting approximately $1.0 million (obligating the Company to repay approximately $58,000 per week for 6 months to 18 months) and issued two (2) convertible loans with a principal balance of $309,000. The terms of the notes are 3-12 months with an interest rate of 5% to 5.77% and convertible into the Company’s common stock at a fixed rate of $2.50 per share. In this time the Company also issued 50,000 shares of common stock and 25 shares of Series BB preferred stock with the convertible loans, 300,000 shares of common stock for accrued interest paid-in-kind and repaid a $300,000 convertible note on April 4, 2023.

Subsequent Events

3 Months Ended

Mar. 31, 2023

7) Subsequent Events

From April 1, 2023 through May 10, 2023 the Company entered into five (5) new merchant cash loan agreements collecting approximately $1.0 million (obligating the Company to repay approximately $58,000 per week for 6 months to 18 months) and issued two (2) convertible loans with a principal balance of $309,000. The terms of the notes are 3-12 months with an interest rate of 5% to 5.77% and convertible into the Company’s common stock at a fixed rate of $2.50 per share. In this time the Company also issued 50,000 shares of common stock and 25 shares of Series BB preferred stock with the convertible loans, 300,000 shares of common stock for accrued interest paid-in-kind and repaid a $300,000 convertible note on April 4, 2023.